GB201716374D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201716374D0
GB201716374D0 GBGB1716374.2A GB201716374A GB201716374D0 GB 201716374 D0 GB201716374 D0 GB 201716374D0 GB 201716374 A GB201716374 A GB 201716374A GB 201716374 D0 GB201716374 D0 GB 201716374D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1716374.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JOP/2019/0192A priority Critical patent/JOP20190192A1/en
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Priority to GBGB1716374.2A priority patent/GB201716374D0/en
Publication of GB201716374D0 publication Critical patent/GB201716374D0/en
Priority to UY0001037622A priority patent/UY37622A/en
Priority to CR20190391A priority patent/CR20190391A/en
Priority to EP18712082.9A priority patent/EP3589618B1/en
Priority to SG11201907546WA priority patent/SG11201907546WA/en
Priority to CA3054754A priority patent/CA3054754A1/en
Priority to PE2019001785A priority patent/PE20191535A1/en
Priority to MX2019010218A priority patent/MX2019010218A/en
Priority to TW107106465A priority patent/TW201841893A/en
Priority to BR112019018028-1A priority patent/BR112019018028A2/en
Priority to ES18712082T priority patent/ES2938269T3/en
Priority to KR1020197028575A priority patent/KR102403176B1/en
Priority to AU2018228651A priority patent/AU2018228651B2/en
Priority to EA201991746A priority patent/EA038888B1/en
Priority to CN201880028604.3A priority patent/CN110582485B/en
Priority to US16/489,859 priority patent/US10966961B2/en
Priority to PCT/EP2018/054733 priority patent/WO2018158212A1/en
Priority to JP2019547351A priority patent/JP6857254B2/en
Priority to IL268565A priority patent/IL268565B/en
Priority to CONC2019/0009020A priority patent/CO2019009020A2/en
Priority to DO2019000221A priority patent/DOP2019000221A/en
Priority to CL2019002480A priority patent/CL2019002480A1/en
Priority to PH12019501999A priority patent/PH12019501999A1/en
Ceased legal-status Critical Current

Links

GBGB1716374.2A 2017-03-01 2017-10-06 Compounds Ceased GB201716374D0 (en)

Priority Applications (24)

Application Number Priority Date Filing Date Title
JOP/2019/0192A JOP20190192A1 (en) 2017-03-01 2017-06-16 Pyrazole derivatives as bromodomain inhibitors
GBGB1716374.2A GB201716374D0 (en) 2017-10-06 2017-10-06 Compounds
JP2019547351A JP6857254B2 (en) 2017-03-01 2018-02-27 Pyrazole derivative as a bromodomain inhibitor
BR112019018028-1A BR112019018028A2 (en) 2017-03-01 2018-02-27 COMPOUND, COMBINATION, E. USE OF A PHARMACEUTICALLY ACCEPTABLE COMPOUND OR SALT OF THE SAME
AU2018228651A AU2018228651B2 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
EP18712082.9A EP3589618B1 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
SG11201907546WA SG11201907546WA (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
CA3054754A CA3054754A1 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
PE2019001785A PE20191535A1 (en) 2017-03-01 2018-02-27 DERIVATIVES OF PIRAZOLE AS BROMODOMINIUM INHIBITORS
MX2019010218A MX2019010218A (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors.
TW107106465A TW201841893A (en) 2017-03-01 2018-02-27 Compounds
UY0001037622A UY37622A (en) 2017-03-01 2018-02-27 PIRAZOL DERIVATIVES AS BET FAMILY BROMODOMINAL INHIBITORS AND THEIR USE IN THERAPEUTIC APPLICATIONS
ES18712082T ES2938269T3 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
KR1020197028575A KR102403176B1 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
CR20190391A CR20190391A (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
EA201991746A EA038888B1 (en) 2017-10-06 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
CN201880028604.3A CN110582485B (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
US16/489,859 US10966961B2 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
PCT/EP2018/054733 WO2018158212A1 (en) 2017-03-01 2018-02-27 Pyrazole derivatives as bromodomain inhibitors
IL268565A IL268565B (en) 2017-03-01 2019-08-07 Pyrazole derivatives as bromodomain inhibitors
CONC2019/0009020A CO2019009020A2 (en) 2017-03-01 2019-08-21 Pyrazole derivatives as bromodomain inhibitors.
DO2019000221A DOP2019000221A (en) 2017-03-01 2019-08-26 DERIVATIVES OF PIRAZOLE AS BROMODOMINIUM INHIBITORS
CL2019002480A CL2019002480A1 (en) 2017-03-01 2019-08-28 Pyrazole derivatives as bromodomain inhibitors.
PH12019501999A PH12019501999A1 (en) 2017-03-01 2019-09-02 Pyrazole derivatives as bromodomain inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1716374.2A GB201716374D0 (en) 2017-10-06 2017-10-06 Compounds

Publications (1)

Publication Number Publication Date
GB201716374D0 true GB201716374D0 (en) 2017-11-22

Family

ID=60326742

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1716374.2A Ceased GB201716374D0 (en) 2017-03-01 2017-10-06 Compounds

Country Status (2)

Country Link
EA (1) EA038888B1 (en)
GB (1) GB201716374D0 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1433788A1 (en) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor Xa inhibitors
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
US9271978B2 (en) * 2012-12-21 2016-03-01 Zenith Epigenetics Corp. Heterocyclic compounds as bromodomain inhibitors

Also Published As

Publication number Publication date
EA038888B1 (en) 2021-11-02
EA201991746A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201704327D0 (en) Compounds
GB201700814D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201720064D0 (en) Compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds
GB201716688D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)